{"count": 32, "results": [{"_id": "34588803", "pmid": 34588803, "pmcid": "PMC8473846", "title": "Retarding Progression of Chronic Kidney Disease in Autosomal Dominant Polycystic Kidney Disease with Metformin and Other Therapies: An Update of New Insights", "journal": "Int J Gen Med", "authors": ["Carullo N", "Zicarelli MT", "Casarella A", "Nicotera R", "Castagna A", "Urso A", "Presta P", "Andreucci M", "Russo E", "Bolignano D", "Coppolino G"], "date": "2021-09-22T00:00:00Z", "doi": "10.2147/IJGM.S305491", "meta_date_publication": "2021", "meta_volume": "14", "meta_issue": "", "meta_pages": "5993-6000", "score": 50284.24, "text_hl": "...The Role of @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ in @<m>DISEASE_Polycystic_Kidney_Autosomal_Dominant</m> @DISEASE_MESH:D016891 @@@ADPKD@@@", "citations": {"NLM": "Carullo N, Zicarelli MT, Casarella A, Nicotera R, Castagna A, Urso A, Presta P, Andreucci M, Russo E, Bolignano D, Coppolino G. Retarding Progression of Chronic Kidney Disease in Autosomal Dominant Polycystic Kidney Disease with Metformin and Other Therapies: An Update of New Insights Int J Gen Med. 2021;14():5993-6000. PMID: 34588803", "BibTeX": "@article{34588803, title={Retarding Progression of Chronic Kidney Disease in Autosomal Dominant Polycystic Kidney Disease with Metformin and Other Therapies: An Update of New Insights}, author={Carullo N and Zicarelli MT and Casarella A and Nicotera R and Castagna A and Urso A and Presta P and Andreucci M and Russo E and Bolignano D and Coppolino G}, journal={Int J Gen Med}, volume={14}, pages={5993-6000}}"}}, {"_id": "40352866", "pmid": 40352866, "title": "Reassessing Metformin's Potential in Autosomal Dominant Polycystic Kidney Disease (ADPKD): A Call for Further Research.", "journal": "Indian J Nephrol", "authors": ["Sethi J"], "date": "2025-05-01T00:00:00Z", "doi": "10.25259/IJN_542_2024", "meta_date_publication": "2025 May-Jun", "meta_volume": "35", "meta_issue": "3", "meta_pages": "444-445", "score": 50281.63, "text_hl": "Reassessing @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@'s Potential in @<m>DISEASE_Polycystic_Kidney_Autosomal_Dominant</m> @DISEASE_MESH:D016891 @@@Autosomal Dominant Polycystic Kidney Disease@@@ (@<m>DISEASE_Polycystic_Kidney_Autosomal_Dominant</m> @DISEASE_MESH:D016891 @@@ADPKD@@@): A Call for Further Research.", "citations": {"NLM": "Sethi J. Reassessing Metformin's Potential in Autosomal Dominant Polycystic Kidney Disease (ADPKD): A Call for Further Research. Indian J Nephrol. 2025 May-Jun;35(3):444-445. PMID: 40352866", "BibTeX": "@article{40352866, title={Reassessing Metformin's Potential in Autosomal Dominant Polycystic Kidney Disease (ADPKD): A Call for Further Research.}, author={Sethi J}, journal={Indian J Nephrol}, volume={35}, number={3}, pages={444-445}}"}}, {"_id": "34391872", "pmid": 34391872, "title": "Metformin Therapy in Autosomal Dominant Polycystic Kidney Disease: A Feasibility Study.", "journal": "Am J Kidney Dis", "authors": ["Brosnahan GM", "Wang W", "Gitomer B", "Struemph T", "George D", "You Z", "Nowak KL", "Klawitter J", "Chonchol MB"], "date": "2022-04-01T00:00:00Z", "doi": "10.1053/j.ajkd.2021.06.026", "meta_date_publication": "2022 Apr", "meta_volume": "79", "meta_issue": "4", "meta_pages": "518-526", "score": 50276.05, "text_hl": "@<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ Therapy in @<m>DISEASE_Polycystic_Kidney_Autosomal_Dominant</m> @DISEASE_MESH:D016891 @@@Autosomal Dominant Polycystic Kidney Disease@@@: A Feasibility Study.", "citations": {"NLM": "Brosnahan GM, Wang W, Gitomer B, Struemph T, George D, You Z, Nowak KL, Klawitter J, Chonchol MB. Metformin Therapy in Autosomal Dominant Polycystic Kidney Disease: A Feasibility Study. Am J Kidney Dis. 2022 Apr;79(4):518-526. PMID: 34391872", "BibTeX": "@article{34391872, title={Metformin Therapy in Autosomal Dominant Polycystic Kidney Disease: A Feasibility Study.}, author={Brosnahan GM and Wang W and Gitomer B and Struemph T and George D and You Z and Nowak KL and Klawitter J and Chonchol MB}, journal={Am J Kidney Dis}, volume={79}, number={4}, pages={518-526}}"}}, {"_id": "33768205", "pmid": 33768205, "title": "Baseline Characteristics and Patient-Reported Outcomes of ADPKD Patients in the Multicenter TAME-PKD Clinical Trial.", "journal": "Kidney360", "authors": ["Seliger SL", "Watnick T", "Althouse AD", "Perrone RD", "Abebe KZ", "Hallows KR", "Miskulin DC", "Bae KT"], "date": "2020-12-31T00:00:00Z", "doi": "10.34067/KID.0004002020", "meta_date_publication": "2020 Dec 31", "meta_volume": "1", "meta_issue": "12", "meta_pages": "1363-1372", "score": 50274.71, "text_hl": "CLINICAL TRIAL REGISTRY NAME AND REGISTRATION NUMBER: @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ as a Novel Therapy for @<m>DISEASE_Polycystic_Kidney_Autosomal_Dominant</m> @DISEASE_MESH:D016891 @@@Autosomal Dominant Polycystic Kidney Disease@@@ (@<m>DISEASE_Polycystic_Kidney_Autosomal_Dominant</m> @DISEASE_MESH:D016891 @@@TAME@@@), NCT02656017.", "citations": {"NLM": "Seliger SL, Watnick T, Althouse AD, Perrone RD, Abebe KZ, Hallows KR, Miskulin DC, Bae KT. Baseline Characteristics and Patient-Reported Outcomes of ADPKD Patients in the Multicenter TAME-PKD Clinical Trial. Kidney360. 2020 Dec 31;1(12):1363-1372. PMID: 33768205", "BibTeX": "@article{33768205, title={Baseline Characteristics and Patient-Reported Outcomes of ADPKD Patients in the Multicenter TAME-PKD Clinical Trial.}, author={Seliger SL and Watnick T and Althouse AD and Perrone RD and Abebe KZ and Hallows KR and Miskulin DC and Bae KT}, journal={Kidney360}, volume={1}, number={12}, pages={1363-1372}}"}}, {"_id": "34420660", "pmid": 34420660, "title": "TAMEing ADPKD with metformin: safe and effective?", "journal": "Kidney Int", "authors": ["Ong ACM", "Gansevoort RT"], "date": "2021-09-01T00:00:00Z", "doi": "10.1016/j.kint.2021.07.021", "meta_date_publication": "2021 Sep", "meta_volume": "100", "meta_issue": "3", "meta_pages": "513-515", "score": 50274.305, "text_hl": "In this issue, Perrone et al. report results from the Trial of Administration of @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ in @DISEASE_Familial_paroxysmal_dystonia @DISEASE_MESH:C537180 @@@PKD@@@ (TAME @DISEASE_Familial_paroxysmal_dystonia @DISEASE_MESH:C537180 @@@PKD@@@) study, a phase 2 randomized controlled trial investigating the safety and tolerability of @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ in @SPECIES_9606 @@@patients@@@ in the early stages of @<m>DISEASE_Polycystic_Kidney_Autosomal_Dominant</m> @DISEASE_MESH:D016891 @@@autosomal dominant polycystic kidney disease@@@. ", "citations": {"NLM": "Ong ACM, Gansevoort RT. TAMEing ADPKD with metformin: safe and effective? Kidney Int. 2021 Sep;100(3):513-515. PMID: 34420660", "BibTeX": "@article{34420660, title={TAMEing ADPKD with metformin: safe and effective?}, author={Ong ACM and Gansevoort RT}, journal={Kidney Int}, volume={100}, number={3}, pages={513-515}}"}}, {"_id": "37675342", "pmid": 37675342, "pmcid": "PMC10479581", "title": "Plant-derived compounds for treating autosomal dominant polycystic kidney disease", "journal": "Front Nephrol", "authors": ["Zhang J", "Chen J", "Xu J", "Xue C", "Mao Z"], "date": "2023-02-03T00:00:00Z", "doi": "10.3389/fneph.2023.1071441", "meta_date_publication": "2023", "meta_volume": "3", "meta_issue": "", "meta_pages": "1071441", "score": 50273.832, "text_hl": "By then, we should have a clear answer as to whether @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ will be effective in the management of @<m>DISEASE_Polycystic_Kidney_Autosomal_Dominant</m> @DISEASE_MESH:D016891 @@@ADPKD@@@.", "citations": {"NLM": "Zhang J, Chen J, Xu J, Xue C, Mao Z. Plant-derived compounds for treating autosomal dominant polycystic kidney disease Front Nephrol. 2023;3():1071441. PMID: 37675342", "BibTeX": "@article{37675342, title={Plant-derived compounds for treating autosomal dominant polycystic kidney disease}, author={Zhang J and Chen J and Xu J and Xue C and Mao Z}, journal={Front Nephrol}, volume={3}, pages={1071441}}"}}, {"_id": "35852784", "pmid": 35852784, "pmcid": "PMC9329410", "title": "Drugs in Clinical Development to Treat Autosomal Dominant Polycystic Kidney Disease", "journal": "Drugs", "authors": ["Bais T", "Gansevoort RT", "Meijer E"], "date": "2022-07-01T00:00:00Z", "doi": "10.1007/s40265-022-01745-9", "meta_date_publication": "2022 Jul", "meta_volume": "82", "meta_issue": "10", "meta_pages": "1095-1115", "score": 50273.57, "text_hl": "By extrapolating these data, they reasoned that @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ should be given in a dose of at least 2000 mg/day to @SPECIES_9606 @@@patients@@@ with @<m>DISEASE_Polycystic_Kidney_Autosomal_Dominant</m> @DISEASE_MESH:D016891 @@@ADPKD@@@ to achieve beneficial effects.", "citations": {"NLM": "Bais T, Gansevoort RT, Meijer E. Drugs in Clinical Development to Treat Autosomal Dominant Polycystic Kidney Disease Drugs. 2022 Jul;82(10):1095-1115. PMID: 35852784", "BibTeX": "@article{35852784, title={Drugs in Clinical Development to Treat Autosomal Dominant Polycystic Kidney Disease}, author={Bais T and Gansevoort RT and Meijer E}, journal={Drugs}, volume={82}, number={10}, pages={1095-1115}}"}}, {"_id": "36660586", "pmid": 36660586, "title": "Combining Metformin and Drug-Loaded Kidney-Targeting Micelles for Polycystic Kidney Disease.", "journal": "Cell Mol Bioeng", "authors": ["Jiang K", "Huang Y", "Chung EJ"], "date": "2022-12-22T00:00:00Z", "doi": "10.1007/s12195-022-00753-9", "meta_date_publication": "2023 Feb", "meta_volume": "16", "meta_issue": "1", "meta_pages": "55-67", "score": 50269.977, "text_hl": "However, despite high tolerability, @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@MET@@@ showed varying therapeutic efficacy in preclinical @<m>DISEASE_Polycystic_Kidney_Autosomal_Dominant</m> @DISEASE_MESH:D016891 @@@ADPKD@@@ studies. ", "citations": {"NLM": "Jiang K, Huang Y, Chung EJ. Combining Metformin and Drug-Loaded Kidney-Targeting Micelles for Polycystic Kidney Disease. Cell Mol Bioeng. 2023 Feb;16(1):55-67. PMID: 36660586", "BibTeX": "@article{36660586, title={Combining Metformin and Drug-Loaded Kidney-Targeting Micelles for Polycystic Kidney Disease.}, author={Jiang K and Huang Y and Chung EJ}, journal={Cell Mol Bioeng}, volume={16}, number={1}, pages={55-67}}"}}, {"_id": "34806449", "pmid": 34806449, "title": "Metformin improves relevant disease parameters in an autosomal dominant polycystic kidney disease mouse model.", "journal": "Am J Physiol Renal Physiol", "authors": ["Pastor-Soler NM", "Li H", "Pham J", "Rivera D", "Ho PY", "Mancino V", "Saitta B", "Hallows KR"], "date": "2022-01-01T00:00:00Z", "doi": "10.1152/ajprenal.00298.2021", "meta_date_publication": "2022 Jan 1", "meta_volume": "322", "meta_issue": "1", "meta_pages": "F27-F41", "score": 50267.984, "text_hl": "@<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ improves relevant disease parameters in an @<m>DISEASE_Polycystic_Kidney_Autosomal_Dominant</m> @DISEASE_MESH:D016891 @@@autosomal dominant polycystic kidney disease@@@ @SPECIES_10090 @@@mouse@@@ model.", "citations": {"NLM": "Pastor-Soler NM, Li H, Pham J, Rivera D, Ho PY, Mancino V, Saitta B, Hallows KR. Metformin improves relevant disease parameters in an autosomal dominant polycystic kidney disease mouse model. Am J Physiol Renal Physiol. 2022 Jan 1;322(1):F27-F41. PMID: 34806449", "BibTeX": "@article{34806449, title={Metformin improves relevant disease parameters in an autosomal dominant polycystic kidney disease mouse model.}, author={Pastor-Soler NM and Li H and Pham J and Rivera D and Ho PY and Mancino V and Saitta B and Hallows KR}, journal={Am J Physiol Renal Physiol}, volume={322}, number={1}, pages={F27-F41}}"}}, {"_id": "41020837", "pmid": 41020837, "title": "Metformin as a Disease-Modifying Agent in Autosomal Dominant Polycystic Kidney Disease: A Systematic Review of Preclinical and Clinical Evidence.", "journal": "Curr Issues Mol Biol", "authors": ["Maciejczyk A", "Niemczyk M"], "date": "2025-09-03T00:00:00Z", "doi": "10.3390/cimb47090715", "meta_date_publication": "2025 Sep 3", "meta_volume": "47", "meta_issue": "9", "meta_pages": "", "score": 50266.812, "text_hl": "@<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ as a Disease-Modifying Agent in @<m>DISEASE_Polycystic_Kidney_Autosomal_Dominant</m> @DISEASE_MESH:D016891 @@@Autosomal Dominant Polycystic Kidney Disease@@@: A Systematic Review of Preclinical and Clinical Evidence.", "citations": {"NLM": "Maciejczyk A, Niemczyk M. Metformin as a Disease-Modifying Agent in Autosomal Dominant Polycystic Kidney Disease: A Systematic Review of Preclinical and Clinical Evidence. Curr Issues Mol Biol. 2025 Sep 3;47(9):. PMID: 41020837", "BibTeX": "@article{41020837, title={Metformin as a Disease-Modifying Agent in Autosomal Dominant Polycystic Kidney Disease: A Systematic Review of Preclinical and Clinical Evidence.}, author={Maciejczyk A and Niemczyk M}, journal={Curr Issues Mol Biol}, volume={47}, number={9}}"}}]}